Case Report: Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder: Diagnostic Challenges and Transition From B-Cell Depletion Therapy to Ravulizumab. (PubMed, Clin Case Rep) - Oct 14, 2026 - "Maintenance of remission without relapse was observed when transitioning from rituximab to eculizumab and then to ravulizumab. Results observed in this case support the use of targeted complement inhibition as relapse-preventive therapy after rituximab."
Journal • CNS Disorders • Neuromyelitis Optica Spectrum Disorder • Rare Diseases
|